Third, some included studies did not stratify results by key patient characteristics (e.g., insulin resistance levels, heart failure clinical phenotypes, cardiac function classification, or SGLT2 inhibitor use in background therapy), potentially limiting the relevance of findings to specific subgroups. Here, SLC5A2 is linked to heart failure.